Our APAC wet lab base of operations — anchored in Biopolis, powered by MiRXES's Industry 4.0 IVD infrastructure, and bridging India's multiomics intelligence to Asia-Pacific's most advanced autonomous manufacturing ecosystem.
India gives us data richness, cost arbitrage, and the world's most diverse genomic population. Singapore gives us regulatory credibility, advanced manufacturing infrastructure, APAC market access, and the IP protection framework that global pharma partners require before committing to co-development deals. The two nodes are strategically complementary — not competitive.
India is where we generate insights — the multiomics data, the AI models, the hypothesis engine. Singapore is where we execute and validate — the i4.0 wet lab, the regulatory dossier, the APAC commercial bridge. Together, they form a closed-loop discovery-to-validation corridor that neither geography alone can offer.
MiRXES is not just a potential wet lab partner — it is the most strategically aligned company in Singapore for our thesis. As an A*STAR spinoff building miRNA-powered multi-cancer early detection with Southeast Asia's most advanced Industry 4.0 IVD manufacturing facility, MiRXES sits at the exact intersection of our multiomics + autonomous lab + APAC market strategy. The partnership is a strategic fit at every dimension.
A*STAR spinoff · Singapore · Founded 2014 · USD $130M raised · HKEX IPO filed · FDA Breakthrough Device Designation
MiRXES brings i4.0 execution infrastructure + miRNA platform + APAC regulatory approvals + J&J-validated commercial model. We bring India multiomics data + OmicsOS AI + LabOS orchestration + India market entry. Neither of us has what the other has. This is a genuine strategic complement, not a vendor relationship.
The BioHelix Node creates a bi-directional discovery corridor. Computational work runs in India (lower cost, larger talent pool). Wet lab validation runs in Singapore via MiRXES's i4.0 infrastructure (regulatory-grade, globally credible). Data flows both ways through LabOS, with OmicsOS continuously learning from every experimental cycle.
Multiomics AI computation
India Biomarker Atlas
Hypothesis generation
Protocol design (NLP)
CDSCO regulatory intelligence
MiRXES i4.0 execution
miRNA + IVD manufacturing
A*STAR validation pipelines
Structured data return
HSA + FDA-bridging dossiers
Customer submits disease area + target class. OmicsOS runs multiomics integration across India cohort data, scRNA-seq, and published literature to generate ranked target list with confidence scores and biomarker candidates.
NLP-driven protocol specification. LabOS checks MiRXES facility inventory, instrument availability, and estimated turnaround via the API integration with their i4.0 scheduling system. Quote generated within hours.
Robotic liquid handling, automated extraction, miRNA profiling, qPCR / next-gen sequencing. "Any mix, any volume" principle allows concurrent execution of multiple experimental arms. All data logged to LabOS in real time.
Structured experimental data returned to OmicsOS. Models update. Next experimental cycle designed. Results packaged for customer as a validated insight report with confidence intervals, reproducibility scores, and recommended next steps.
For programs requiring regulatory-grade output: HSA (Singapore) dossier first. Then FDA/EMA bridging via MiRXES's existing Breakthrough Device experience. CDSCO India dossier generated in parallel for domestic programs.
Singapore's Health Sciences Authority (HSA) is one of the most progressive regulatory agencies in Asia and is recognized as a reference agency by ASEAN member states. HSA approval creates a direct pathway for ASEAN market access, and Singapore's existing bilateral recognition agreements with the EU and US create a validated stepping-stone for global filings.
MiRXES holds FDA Breakthrough Device Designation (BDD) for GASTROClear — providing a validated regulatory navigation template for our co-developed programs.
The relationship with MiRXES should evolve across three tiers, starting with a services arrangement and progressing toward co-IP and joint ventures as the relationship deepens and mutual value is demonstrated.
| Tier | Model | What We Access | What MiRXES Gets | Timeline |
|---|---|---|---|---|
| Tier 1 | Lab Services / CRO | i4.0 facility access, instrument time, scientist hours, data return via LabOS API | Revenue from lab services, our AI-driven experimental efficiency increases their throughput | Months 1–12 |
| Tier 2 | Technology Partnership | ID3EAL platform integration into OmicsCloud, joint protocol development, MiRXES brand on our Singapore offerings | OmicsOS multiomics capability added to ID3EAL, India market entry via our network, co-branded APAC positioning | Months 6–24 |
| Tier 3 | Co-IP / Joint Venture | Shared IP on India-validated + Singapore-executed biomarker panels, joint regulatory dossiers, co-commercialization | Equity in India biomarker programs, revenue share on APAC sales of jointly developed diagnostics, BioHelix-branded venture | Year 2–3+ |
| Tier 4 | BioHelix Singapore JV | Shared Singapore legal entity, combined Singapore investor access (EDBI, Temasek/ClavystBio), joint HKEX/SGX narrative | India commercialization of GASTROClear-class products via Apollo/hospital network, shared APAC discovery platform | Year 3–5 |
MiRXES has explicitly stated its ambition to expand across Southeast Asia (Thailand, Malaysia, Indonesia via the EnterpriseSG Scale-up SG programme) — but India is conspicuously absent from their current expansion map. With 1.4 billion people, the world's highest gastric cancer burden in certain populations, and Apollo's 10,000+ bed hospital network, India is MiRXES's biggest untapped market — and we are the only team positioned to unlock it for them.
35,000 sq ft of BSL-2 certified co-working wet labs across 3 sites. Flexible "plug-and-play" operational from day one. Partnered with Merck, Temasek's ClavystBio, and Amgen. Our Singapore team office base before dedicated space.
Diagnostics Development Hub — Singapore's national platform for translating diagnostics from research to commercial readiness. Co-funded multiple MiRXES programs. Access pathway for our biomarker panels.
A*STAR institute at Biopolis. SEAGOS (SEA Genomics) datasets. Singapore Chinese, Malay, and Indian population genomics. Complements our India cohort data — combined India + SEA reference genome capability.
Government deep-tech VC programs. SGInnovate co-invests with private VCs. EDBI (EDB's investment arm) takes strategic stakes in Singapore-based biotech. Both have healthcare mandates aligned with our thesis.
Flagship (creator of Moderna) signed a S$100M co-investment MoU with A*STAR for Singapore biotech. Direct access to Flagship Pioneering's venture creation model — the global gold standard for biotech studio building.
Pfizer, Novartis, AZ, Roche, J&J, Sanofi, Takeda — all have Singapore APAC HQs. BD conversations happen in Singapore. Our BioHelix Node puts us in the same room as the APAC heads of R&D partnerships at all major pharma.
| Role | Hire Timeline | Profile | Why Singapore-Based |
|---|---|---|---|
| Head of Singapore Operations | Month 3–6 | Ex-A*STAR / MNC pharma. Regulatory + BD background. Singapore PR or citizen. | Local BD relationships, HSA regulatory navigation, MiRXES liaison |
| Molecular Biologist / Lab Scientist | Month 6–9 | PhD, NGS/miRNA experience. Biopolis background preferred. | On-site at MiRXES facility to oversee experimental execution quality |
| Regulatory Affairs Specialist | Month 9–12 | HSA submission experience, ASEAN harmonization knowledge, IVD background. | Singapore is the regulatory dossier hub for all APAC programs |
We are not a single-country bet. We have secured operational access to Southeast Asia's most advanced Industry 4.0 IVD manufacturing facility as our wet lab partner. We sit within the Biopolis ecosystem — the same hub that houses Pfizer, Novartis, AZ, Roche, and 40+ global pharma R&D operations. Our Singapore entity provides IP protection, APAC regulatory credibility, and sovereign wealth investor access that an India-only company cannot offer. The India–Singapore corridor is our structural competitive moat.
Global pharma and Western VCs often hesitate at India-only biotech. Singapore as the execution and regulatory node signals global ambition, credible IP protection (strong SG IP law), and APAC commercial readiness. Instantly upgrades the investment thesis.
Temasek (via ClavystBio), GIC, and EDBI all require Singapore operational presence for meaningful capital deployment. Singapore entity unlocks a capital pool that India-only structure cannot access — potentially $20–50M at Series A/B.